Logo image of BVS

BIOVENTUS INC - A (BVS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BVS - US09075A1088 - Common Stock

7.19 USD
0 (0%)
Last: 12/9/2025, 8:00:02 PM
7.19 USD
0 (0%)
After Hours: 12/9/2025, 8:00:02 PM
Fundamental Rating

5

Taking everything into account, BVS scores 5 out of 10 in our fundamental rating. BVS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While BVS is still in line with the averages on profitability rating, there are concerns on its financial health. BVS scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year BVS was profitable.
BVS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BVS reported negative net income in multiple years.
Of the past 5 years BVS 4 years had a positive operating cash flow.
BVS Yearly Net Income VS EBIT VS OCF VS FCFBVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

BVS's Return On Assets of 1.11% is fine compared to the rest of the industry. BVS outperforms 75.40% of its industry peers.
With a decent Return On Equity value of 4.71%, BVS is doing good in the industry, outperforming 76.47% of the companies in the same industry.
BVS has a better Return On Invested Capital (6.62%) than 80.75% of its industry peers.
Industry RankSector Rank
ROA 1.11%
ROE 4.71%
ROIC 6.62%
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
BVS Yearly ROA, ROE, ROICBVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

The Profit Margin of BVS (1.39%) is better than 74.33% of its industry peers.
BVS has a Operating Margin of 8.03%. This is in the better half of the industry: BVS outperforms 75.40% of its industry peers.
In the last couple of years the Operating Margin of BVS has declined.
With a decent Gross Margin value of 67.76%, BVS is doing good in the industry, outperforming 72.19% of the companies in the same industry.
In the last couple of years the Gross Margin of BVS has declined.
Industry RankSector Rank
OM 8.03%
PM (TTM) 1.39%
GM 67.76%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
BVS Yearly Profit, Operating, Gross MarginsBVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

3

2. Health

2.1 Basic Checks

BVS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BVS has more shares outstanding
Compared to 5 years ago, BVS has more shares outstanding
BVS has a better debt/assets ratio than last year.
BVS Yearly Shares OutstandingBVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BVS Yearly Total Debt VS Total AssetsBVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.19, we must say that BVS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BVS (1.19) is comparable to the rest of the industry.
BVS has a debt to FCF ratio of 6.22. This is a slightly negative value and a sign of low solvency as BVS would need 6.22 years to pay back of all of its debts.
BVS has a better Debt to FCF ratio (6.22) than 76.47% of its industry peers.
A Debt/Equity ratio of 1.93 is on the high side and indicates that BVS has dependencies on debt financing.
With a Debt to Equity ratio value of 1.93, BVS is not doing good in the industry: 80.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.93
Debt/FCF 6.22
Altman-Z 1.19
ROIC/WACC0.78
WACC8.53%
BVS Yearly LT Debt VS Equity VS FCFBVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 1.74 indicates that BVS should not have too much problems paying its short term obligations.
The Current ratio of BVS (1.74) is worse than 68.98% of its industry peers.
A Quick Ratio of 1.14 indicates that BVS should not have too much problems paying its short term obligations.
BVS's Quick ratio of 1.14 is on the low side compared to the rest of the industry. BVS is outperformed by 72.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.14
BVS Yearly Current Assets VS Current LiabilitesBVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

5

3. Growth

3.1 Past

BVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.28%, which is quite impressive.
Measured over the past years, BVS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.93% on average per year.
BVS shows a small growth in Revenue. In the last year, the Revenue has grown by 1.58%.
Measured over the past years, BVS shows a quite strong growth in Revenue. The Revenue has been growing by 11.01% on average per year.
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)1.58%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%

3.2 Future

BVS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.51% yearly.
Based on estimates for the next years, BVS will show a small growth in Revenue. The Revenue will grow by 4.43% on average per year.
EPS Next Y41.83%
EPS Next 2Y31.93%
EPS Next 3Y25.51%
EPS Next 5YN/A
Revenue Next Year0.33%
Revenue Next 2Y3.66%
Revenue Next 3Y4.43%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BVS Yearly Revenue VS EstimatesBVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
BVS Yearly EPS VS EstimatesBVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 12.19, BVS is valued correctly.
Based on the Price/Earnings ratio, BVS is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
BVS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.28.
Based on the Price/Forward Earnings ratio of 8.79, the valuation of BVS can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BVS indicates a rather cheap valuation: BVS is cheaper than 95.19% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of BVS to the average of the S&P500 Index (23.52), we can say BVS is valued rather cheaply.
Industry RankSector Rank
PE 12.19
Fwd PE 8.79
BVS Price Earnings VS Forward Price EarningsBVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

93.05% of the companies in the same industry are more expensive than BVS, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BVS indicates a rather cheap valuation: BVS is cheaper than 95.72% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.13
EV/EBITDA 9.52
BVS Per share dataBVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

BVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BVS's earnings are expected to grow with 25.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y31.93%
EPS Next 3Y25.51%

0

5. Dividend

5.1 Amount

No dividends for BVS!.
Industry RankSector Rank
Dividend Yield N/A

BIOVENTUS INC - A

NASDAQ:BVS (12/9/2025, 8:00:02 PM)

After market: 7.19 0 (0%)

7.19

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners74.46%
Inst Owner Change1.06%
Ins Owners2.51%
Ins Owner Change-0.23%
Market Cap595.04M
Revenue(TTM)563.83M
Net Income(TTM)7.82M
Analysts80
Price Target15.3 (112.8%)
Short Float %3.19%
Short Ratio6.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.08%
Min EPS beat(2)-0.99%
Max EPS beat(2)29.14%
EPS beat(4)3
Avg EPS beat(4)86.47%
Min EPS beat(4)-0.99%
Max EPS beat(4)239.51%
EPS beat(8)7
Avg EPS beat(8)133.13%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.3%
Min Revenue beat(2)-0.67%
Max Revenue beat(2)0.07%
Revenue beat(4)2
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-0.67%
Max Revenue beat(4)4.79%
Revenue beat(8)6
Avg Revenue beat(8)4.08%
Revenue beat(12)9
Avg Revenue beat(12)2.76%
Revenue beat(16)10
Avg Revenue beat(16)1.33%
PT rev (1m)2.27%
PT rev (3m)2.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.27%
EPS NY rev (1m)3.13%
EPS NY rev (3m)2.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.31%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE 12.19
Fwd PE 8.79
P/S 1.06
P/FCF 11.13
P/OCF 10.62
P/B 3.58
P/tB N/A
EV/EBITDA 9.52
EPS(TTM)0.59
EY8.21%
EPS(NY)0.82
Fwd EY11.38%
FCF(TTM)0.65
FCFY8.99%
OCF(TTM)0.68
OCFY9.42%
SpS6.81
BVpS2.01
TBVpS-2.64
PEG (NY)0.29
PEG (5Y)N/A
Graham Number5.16
Profitability
Industry RankSector Rank
ROA 1.11%
ROE 4.71%
ROCE 8.38%
ROIC 6.62%
ROICexc 7.18%
ROICexgc 31.69%
OM 8.03%
PM (TTM) 1.39%
GM 67.76%
FCFM 9.48%
ROA(3y)-11.81%
ROA(5y)-6.59%
ROE(3y)-54.27%
ROE(5y)-31.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y44.62%
ROICexgc growth 5Y-8.7%
ROICexc growth 3Y36.86%
ROICexc growth 5Y-12.41%
OM growth 3Y-2.88%
OM growth 5Y-14.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y-1.56%
F-Score8
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 1.93
Debt/FCF 6.22
Debt/EBITDA 3.44
Cap/Depr 5.36%
Cap/Sales 0.45%
Interest Coverage 250
Cash Conversion 60.26%
Profit Quality 683.69%
Current Ratio 1.74
Quick Ratio 1.14
Altman-Z 1.19
F-Score8
WACC8.53%
ROIC/WACC0.78
Cap/Depr(3y)9.96%
Cap/Depr(5y)13.06%
Cap/Sales(3y)1.19%
Cap/Sales(5y)1.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.28%
EPS 3Y-16.93%
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y41.83%
EPS Next 2Y31.93%
EPS Next 3Y25.51%
EPS Next 5YN/A
Revenue 1Y (TTM)1.58%
Revenue growth 3Y9.98%
Revenue growth 5Y11.01%
Sales Q2Q%-0.23%
Revenue Next Year0.33%
Revenue Next 2Y3.66%
Revenue Next 3Y4.43%
Revenue Next 5YN/A
EBIT growth 1Y178.93%
EBIT growth 3Y6.82%
EBIT growth 5Y-5.11%
EBIT Next Year16.21%
EBIT Next 3Y12.52%
EBIT Next 5YN/A
FCF growth 1Y29806.1%
FCF growth 3Y34.24%
FCF growth 5Y-0.3%
OCF growth 1Y448.75%
OCF growth 3Y19.05%
OCF growth 5Y-0.96%

BIOVENTUS INC - A / BVS FAQ

Can you provide the ChartMill fundamental rating for BIOVENTUS INC - A?

ChartMill assigns a fundamental rating of 5 / 10 to BVS.


What is the valuation status of BIOVENTUS INC - A (BVS) stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOVENTUS INC - A (BVS). This can be considered as Undervalued.


Can you provide the profitability details for BIOVENTUS INC - A?

BIOVENTUS INC - A (BVS) has a profitability rating of 5 / 10.


How financially healthy is BIOVENTUS INC - A?

The financial health rating of BIOVENTUS INC - A (BVS) is 3 / 10.


What is the earnings growth outlook for BIOVENTUS INC - A?

The Earnings per Share (EPS) of BIOVENTUS INC - A (BVS) is expected to grow by 41.83% in the next year.